NAD+ (nicotinamide-adenine-dinucleotide) blijkt belangrijk te zijn met betrekking tot de cardiovasculaire gezondheid. Als co-enzym speelt NAD+ een rol in biochemische processen die van invloed zijn op het hart- en vaatstelsel, zoals de energiestofwisseling, endotheelfunctie en oxidatieve stress. Toepassing van NAD+-precursors zoals nicotinamide, tezamen met het natuurlijke pentose-D-ribose, zou een nieuwe metabole aanpak kunnen zijn als behandelstrategie bij hart- en vaatziekten zoals hartfalen, hypertensie en atherosclerose.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Verschenen in
Referenties
Abdellatif M, Bugger H, Kroemer G, Sedej S. NAD+ and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities. J Lipid Atheroscler. 2022 May;11(2):111–32.
Zhang X, Zhang Y, Sun A, Ge J. The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: Molecular mechanisms, roles and therapeutic potential. Genes Dis. 2022 Jul 1;9(4):959–72.
Krueger KJ, Rahman FK, Shen Q, Vacek J, Hiebert JB, Pierce JD. Mitochondrial bioenergetics and D-ribose in HFpEF: a brief narrative review. Ann Transl Med. 2021 Oct;9(19):1504.
Matasic DS, Brenner C, London B. Emerging potential benefits of modulating NAD+ metabolism in cardiovascular disease. Am J Physiol-Heart Circ Physiol. 2018 Apr;314(4):H839–52.
Xu W, Li L, Zhang L. NAD+ Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death. Front Physiol [Internet]. 2020 [cited 2024 Jan 9];11. Available from: https://www.frontiersin.org/articles/10.3389/fphys.2020.00901
Mericskay M. Nicotinamide adenine dinucleotide homeostasis and signalling in heart disease: Pathophysiological implications and therapeutic potential. Arch Cardiovasc Dis. 2016 Mar 1;109(3):207–15.
Borradaile NM, Pickering JG. NAD+, Sirtuins, and Cardiovascular Disease. Curr Pharm Des. 2009 Jan 1;15(1):110–7.
Kane AE, Sinclair DA. Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases. Circ Res. 2018 Sep 14;123(7):868–85.
Tong D, Schiattarella GG, Jiang N, Altamirano F, Szweda PA, Elnwasany A, et al. NAD+ Repletion Reverses Heart Failure With Preserved Ejection Fraction. Circ Res. 2021 May 28;128(11):1629–41.
10. Abdellatif M, Trummer-Herbst V, Koser F, Durand S, Adão R, Vasques-Nóvoa F, et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci Transl Med. 2021 Feb 10;13(580):eabd7064MacCarter D, Vijay N, Washam M, Shecterle L, Sierminski H, St Cyr JA. D-ribose aids advanced ischemic heart failure patients. Int J Cardiol. 2009 Sep 11;137(1):79–80.
Meng Xuyang, Li Yi. Efficacy of Nicotinamide Adenine Dinucleotide in Heart Failure Patients: A randomized, double-blind, placebo-control clinical trial [Internet]. 2023 [cited 2024 Jan 9]. Available from: https://www.researchsquare.com
Lei L, Zhang X, Lin J, Liang Q, Sohouli MH, Izze da Silva Magalhães E, et al. Effects of NAD+ precursors on blood pressure, C-reactive protein concentration and carotid intima-media thickness: A meta-analysis of randomized controlled trials. Eur J Clin Invest. 2023 Dec;53(12):e14078.
Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2023 Feb 16;13(1):2786.
Li X, Yang H, Jin H, Turkez H, Ozturk G, Doganay HL, et al. The acute effect of different NAD+ precursors included in the combined metabolic activators. Free Radic Biol Med. 2023 Aug 20;205:77–89.
Sinatra ST. Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern Ther Health Med. 2009;15(3):44–52.
